Document:

<PAGE>
                                                                    Exhibit 10.4

                                                            BLAKE DAWSON WALDRON
                                                                   LAWYERS

                              AMENDED AND RE-STATED
                                AGENCY AGREEMENT

                                 GLYCOTEX, INC.

                        NOVOGEN LABORATORIES PTY LIMITED
                               ABN 42 002 489 947

                                Level 35
                       225 George Street
                         Sydney NSW 2000
              Telephone: +61 2 9258 6000
                    Fax: +61 2 9258 6999   REF: BLM SJH 02 1389 1453

                          (C) BLAKE DAWSON WALDRON 2005
<PAGE>
                                    CONTENTS

<TABLE>
<S>                                                                           <C>
1.   INTERPRETATION                                                            1

   1.1    Definitions                                                          1
   1.2    Rules for interpreting this document                                 4
   1.3    Business Days                                                        5

2.   APPOINTMENT OF AGENT                                                      5

   2.1    Appointment                                                          5
   2.2    Acceptance of appointment                                            5

3.   AGENCY OBLIGATIONS                                                        6

   3.1    Negotiation of Clinical Trial Agreements                             6
   3.2    Execution of Clinical Trial Agreements                               6
   3.3    Performance of Clinical Trial Agreements                             6
   3.4    Appropriate personnel                                                6
   3.5    Care, skill, etc.                                                    6
   3.6    Judgment                                                             7
   3.7    Assistance by Glycotex                                               7

4.   FEES                                                                      7

   4.1    Fees and disbursements                                               7
   4.2    Invoices                                                             7
   4.3    Payment of invoices                                                  7
   4.4    Payments                                                             7
   4.5    Interest on overdue accounts                                         7

5.   GOODS AND SERVICES TAX                                                    8

   5.1    GST Law definitions                                                  8
   5.2    GST payable in addition to other amounts                             8
   5.3    Tax invoice                                                          8
   5.4    Adjustments                                                          9
   5.5    GST where Glycotex supplies Novogen Laboratories                     9

6.   MATERIALS AND INTELLECTUAL PROPERTY RIGHTS                                9

   6.1    Materials and information                                            9
   6.2    Intellectual Property Rights                                         9

7.   CONFIDENTIAL INFORMATION                                                  9

   7.1    Confidentiality                                                      9
   7.2    Exceptions to obligations of confidentiality                        10
   7.3    Public domain                                                       10
</TABLE>
<PAGE>
<TABLE>
<S>                                                                           <C>
8.   REPRESENTATIONS AND WARRANTIES                                           10

   8.1    Warranties of each party                                            10
   8.2    Reliance on representations and warranties                          11
   8.3    Exclusion of conditions and warranties                              11

9.   LIMITATION OF LIABILITY AND INDEMNITY                                    11

   9.1    Indirect and consequential loss                                     11
   9.2    Indemnity                                                           11

10.  FORCE MAJEURE                                                            12

   10.1   Notice and suspension of obligations                                12
   10.2   Effort to overcome                                                  12
   10.3   Termination                                                         12

11.  TERM AND TERMINATION                                                     12

   11.1   Term                                                                12
   11.2   Termination by Glycotex                                             12
   11.3   Termination by Novogen Laboratories                                 13
   11.4   Consequences of termination                                         13
   11.5   Survival and accrued rights                                         13

12.  DISPUTE RESOLUTION                                                       14

   12.1   Disputes                                                            14
   12.2   Notice of Dispute                                                   14
   12.3   Negotiation                                                         14
   12.4   Resolution of Dispute                                               14
   12.5   Mediation                                                           14

13.  NOTICES                                                                  15

14.  AMENDMENT AND ASSIGNMENT                                                 15

   14.1   Amendment                                                           15
   14.2   Assignment                                                          15

15.  GENERAL                                                                  15

   15.1   Governing law                                                       15
   15.2   Liability for expenses                                              15
   15.3   Relationship of the parties                                         16
   15.4   Giving effect to this document                                      16
   15.5   Waiver of rights                                                    16
   15.6   Operation of this document                                          16
   15.7   Exclusion of contrary legislation                                   16
   15.8   Counterparts                                                        17
</TABLE>

                                                                             ii.
<PAGE>
                     AMENDED AND RE-STATED AGENCY AGREEMENT

DATE SEPTEMBER 2005

PARTIES

     GLYCOTEX, INC., a company incorporated under the laws of Delaware, United
     States of America, c/- 1 Landmark Square, Suite 240, Stamford Connecticut
     06901, USA (GLYCOTEX)

     NOVOGEN LABORATORIES PTY LTD ABN 42 002 489 947 (NOVOGEN LABORATORIES)

RECITALS

A.   Glycotex has a worldwide exclusive licence to exploit certain Intellectual
     Property Rights relating to Glucan Products.

B.   Novogen Laboratories has expertise and experience in the arrangement and
     negotiation of agreements for the conduct of clinical trials of
     pharmaceutical products in Australia and the conduct of such clinical
     trials.

C.   Glycotex appointed Novogen Laboratories as its agent to negotiate and enter
     into Clinical Trial Agreements on the terms and conditions of an Agency
     Agreement dated 30 April 2003.

D.   The parties now amend and re-state the Agency Agreement in accordance with
     this document.

OPERATIVE PROVISIONS

1.   INTERPRETATION

1.1  DEFINITIONS

     The following definitions apply in this document.

     BUSINESS DAY means a day that is not a Saturday, Sunday or public holiday
     in Sydney, Australia.

     CHANGE IN CONTROL, in relation to Glycotex means:

     (a)  the acquisition by any Person or Group other than Novogen Limited of
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of directors of
          Glycotex; or

     (b)  any merger, consolidation, reorganization, recapitalization, tender or
          exchange offer or any other transaction with or effecting Glycotex as
          a result of which a Person or Group other than the stockholders of
          Glycotex immediately before the transaction owns after the transaction
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of the directors
          of Glycotex,
<PAGE>
     but does not include any acquisition as a result of, or transaction
     involving, an initial public offering of Glycotex's common stock.

     CLINICAL TRIAL means a clinical evaluation of the stability, tolerability,
     synergy or efficacy of a Glucan Product in the Field.

     CLINICAL TRIAL AGREEMENTS means agreements for the conduct of Clinical
     Trials with:

     (a)  Royal North Shore Hospital;

     (b)  Blacktown Hospital; and

     (c)  Sutherland Hospital,

     and such other parties as Glycotex notifies Novogen Laboratories from time
     to time during the Term.

     COMMENCEMENT DATE means the date this document is executed by the last of
     the parties to execute it.

     CONFIDENTIAL INFORMATION means:

     (a)  all Know How relating to Glucan Products and Clinical Trials;

     (b)  all Know How created in the course of or as a result of Clinical
          Trials;

     (c)  all written or oral information disclosed by Glycotex to Novogen
          Laboratories under this document; and

     (d)  all written or oral information coming to the knowledge of Novogen
          Laboratories in the performance of its obligations as agent under this
          document,

     other than information which Novogen Laboratories can establish:

     (e)  was in the public domain when it was given to Novogen Laboratories;

     (f)  becomes, after being given to Novogen Laboratories, part of the public
          domain, except through disclosure contrary to this document; or

     (g)  was lawfully received by Novogen Laboratories from another person
          having the unrestricted legal right to disclose that information
          without requiring the maintenance of confidentiality.

     CORPORATIONS ACT means the Corporations Act 2001 (Cth).

     DEFAULT RATE means, in relation to an amount which has not been paid to a
     party, a rate equal to the sum of that party's cost of funding the amount
     (if that party were to borrow that amount and as determined conclusively by
     that party) and 2% per annum.

     DISPUTE has the meaning given to that term in clause 12.1.

                                                                              2.
<PAGE>
     DISPUTE NOTICE has the meaning given to that term in clause 12.2.

     FIELD means the fields of:

     (a)  therapeutic treatment of skin ulceration (including pressure sores,
          bed sores, venous ulcers, diabetic ulcers and burns) in humans;

     (b)  treatment of bone fracture and the enhancement of fixation of
          implanted orthopaedic devices (including pins, screws and artificial
          joints) in humans;

     (c)  prevention/treatment of ultraviolet light induced skin damage in
          humans;

     (d)  treatment of injured connective tissues (including injuries to tendons
          and ligaments, such as sporting injuries, inflammation and surgical
          injury) in humans;

     (e)  joint repair (particularly with artificial joints) in humans; and

     (f)  treatment of poorly healing surgically dissected or transected tissue
          in humans.

     GLUCAN PRODUCT means any product or formulation containing
     (beta)-(1,3)(1,6) glucan for use in the Field.

     GOVERNMENT AGENCY means:

     (a)  a government or government department or other body;

     (b)  a governmental, semi-governmental or judicial person; or

     (c)  a person (whether autonomous or not) who is charged with the
          administration of a law.

     GROUP means two or more Persons acting as a partnership, limited
     partnership, syndicate, or other group for the purpose of acquiring,
     holding, or disposing of any securities.

     GST means:

     (a)  the same as in the GST Law; and

     (b)  any other goods and services tax, or any tax applying to this
          transaction in a similar way; and

     (c)  any additional tax, penalty tax, fine, interest or other charge under
          a law for such a tax.

     GST LAW means the same as "GST law" means in A New Tax System (Goods and
     Services Tax) Act 1999 (Cth).

     INSOLVENCY EVENT means, for a person, being in liquidation or provisional
     liquidation or under administration, having a controller or analogous
     person appointed to it or any of its property, being taken to have failed
     to comply with a statutory demand, being unable to pay its debts or
     otherwise insolvent, dying, ceasing to be of full legal capacity or
     otherwise

                                                                              3.
<PAGE>
     becoming incapable of managing its own affairs for any reason, taking any
     step that could result in the person becoming an insolvent under
     administration, entering into a compromise or arrangement with, or
     assignment for the benefit of, any of its members or creditors, or any
     analogous event.

     INTELLECTUAL PROPERTY RIGHTS means any and all existing and future
     intellectual and industrial property rights throughout the world, whether
     conferred by statute, common law or equity, including rights in relation to
     copyright, trade marks, designs, circuit layouts, plant varieties, business
     and domain names, trade secrets and Know How (including the right to apply
     for registration of any such rights), Patent Rights and other results of
     intellectual activity in the industrial, commercial, scientific, literary
     or artistic fields.

     KNOW HOW means technical and other information which is not in the public
     domain including inventions, discoveries, concepts, data, formulae, ideas,
     specifications, procedures for experiments and tests, results of
     experimentation and testing, results of research and development and
     information in laboratory records, data collected during the course of
     clinical trials, case reports, data analyses and summaries and submissions
     to and information from ethics committees and regulatory authorities.

     PATENT RIGHTS means existing and future patents (including any divisions,
     continuations, continuations in part, renewals, reissues, extensions,
     supplementary protection certificates, utility models and foreign
     equivalents thereof) and rights with respect to existing and future patent
     applications and patentable inventions, including the right to apply for
     registration of any such rights.

     PERSON means a natural person, company, government, or political
     subdivision, agency, or instrumentality of a government.

     TERM means the term of this document as determined under clause 11.

1.2  RULES FOR INTERPRETING THIS DOCUMENT

     Headings are for convenience only, and do not affect interpretation. The
     following rules also apply in interpreting this document, except where the
     context makes it clear that a rule is not intended to apply.

     (a)  A reference to:

          (i)  legislation (including subordinate legislation) is to that
               legislation as amended, re-enacted or replaced, and includes any
               subordinate legislation issued under it;

          (ii) a document or agreement, or a provision of a document or
               agreement, is to that document, agreement or provision as
               amended, supplemented, replaced or novated;

          (iii) a party to this document or to any other document or agreement
               includes a permitted substitute or a permitted assign of that
               party;

                                                                              4.
<PAGE>
          (iv) a person includes any type of entity or body of persons, whether
               or not it is incorporated or has a separate legal identity, and
               any executor, administrator or successor in law of the person;
               and

          (v)  anything (including a right, obligation or concept) includes each
               part of it.

     (b)  A singular word includes the plural, and vice versa.

     (c)  A word which suggests one gender includes the other genders.

     (d)  If a word is defined, another part of speech has a corresponding
          meaning.

     (e)  If an example is given of anything (including a right, obligation or
          concept), such as by saying it includes something else, the example
          does not limit the scope of that thing.

     (f)  The word AGREEMENT includes an undertaking or other binding
          arrangement or understanding, whether or not in writing.

     (g)  The words SUBSIDIARY, HOLDING COMPANY and RELATED BODY CORPORATE have
          the same meanings as in the Corporations Act.

1.3  BUSINESS DAYS

     If the day on or by which a person must do something under this document is
     not a Business Day:

     (a)  if the act involves a payment that is due on demand, the person must
          do it on or by the next Business Day; and

     (b)  in any other case, the person must do it on or by the previous
          Business Day.

2.   APPOINTMENT OF AGENT

2.1  APPOINTMENT

     Glycotex appoints Novogen Laboratories as its agent to:

     (a)  arrange and negotiate Clinical Trial Agreements;

     (b)  enter into Clinical Trial Agreements on reasonable commercial terms;
          and

     (c)  perform Glycotex's obligations under Clinical Trial Agreements.

2.2  ACCEPTANCE OF APPOINTMENT

     Novogen Laboratories accepts its appointment under clause 2.1 on the terms
     and conditions of this document.

                                                                              5.
<PAGE>
3.   AGENCY OBLIGATIONS

3.1  NEGOTIATION OF CLINICAL TRIAL AGREEMENTS

     Novogen Laboratories must:

     (a)  use all reasonable endeavours to negotiate Clinical Trial Agreements
          on the most favourable commercial terms available;

     (b)  keep Glycotex regularly informed of the status and progress of the
          negotiation of Clinical Trial Agreements;

     (c)  comply with Glycotex's reasonable directions in the negotiation of
          Clinical Trial Agreements; and

     (d)  enter into Clinical Trial Agreements as agent for Glycotex on
          Glycotex's written direction.

3.2  EXECUTION OF CLINICAL TRIAL AGREEMENTS

     Novogen Laboratories must not enter into any Clinical Trial Agreement or
     commit Glycotex to any obligation under any Clinical Trial Agreement
     without Glycotex's prior written consent.

3.3  PERFORMANCE OF CLINICAL TRIAL AGREEMENTS

     Novogen Laboratories must:

     (a)  perform the obligations of Glycotex under any Clinical Trial
          Agreements as agent for Glycotex;

     (b)  not cause Glycotex to breach any obligation under any Clinical Trial
          Agreements; and

     (c)  keep Glycotex regularly informed of the performance of Clinical Trial
          Agreements and the status and progress of all Clinical Trials.

3.4  APPROPRIATE PERSONNEL

     Novogen Laboratories shall ensure that its employees, agents and
     consultants have appropriate qualifications and experience to perform its
     obligations under this document, having regard to the nature of those
     obligations.

3.5  CARE, SKILL, ETC.

     Novogen Laboratories shall perform its obligations under this document:

     (a)  diligently, competently and with reasonable care and skill; and

     (b)  in compliance with all applicable laws and regulations.

                                                                              6.
<PAGE>
3.6  JUDGMENT

     Nothing in this clause 3 prevents Novogen Laboratories from exercising its
     judgment and utilising its skills as it considers most appropriate to
     perform its obligations as agent under this document.

3.7  ASSISTANCE BY GLYCOTEX

     Glycotex must give Novogen Laboratories such assistance as Novogen
     Laboratories reasonably requests in order to perform its obligations as
     agent under this document.

4.   FEES

4.1  FEES AND DISBURSEMENTS

     Glycotex must pay to Novogen Laboratories, in accordance with clause 4.3:

     (a)  all amounts paid by Novogen Laboratories on behalf of Glycotex under
          or pursuant to any Clinical Trial Agreements;

     (b)  all reasonable out of pocket expenses (including travel and
          accommodation expenses) incurred by Novogen Laboratories each month in
          the course of performance of:

          (i)  its obligations under this document; and

          (ii) Glycotex's obligations under Clinical Trial Agreements; and

     (c)  an agency fee of 2% of the total of the amounts in clauses 4.1(a) and
          (b).

4.2  INVOICES

     Within 7 days of the end of each month, Novogen Laboratories shall render
     to Glycotex a written invoice for payment of the amounts payable under
     clause 4.1 in that month.

4.3  PAYMENT OF INVOICES

     Glycotex shall pay the amount of all correctly rendered invoices within 7
     days of the date of the invoice.

4.4  PAYMENTS

     All amounts due and payable under clause 4.3 must be calculated and paid in
     United States dollars and must be paid by bank cheque or electronic
     transfer to an account notified by Novogen Laboratories in writing.

4.5  INTEREST ON OVERDUE ACCOUNTS

     Interest shall accrue at the Default Rate on the outstanding balance of all
     overdue amounts payable under clause 4.3, calculated daily.

                                                                              7.
<PAGE>
5.   GOODS AND SERVICES TAX

5.1  GST LAW DEFINITIONS

     Words defined in the GST Law have the same meaning in this clause 5 unless
     the context makes it clear that a different meaning is intended.

5.2  GST PAYABLE IN ADDITION TO OTHER AMOUNTS

     In addition to paying all amounts payable by Glycotex under this document,
     Glycotex must:

     (a)  pay to Novogen Laboratories an amount equal to any GST payable on any
          supply by Novogen Laboratories under or in connection with this
          document without deduction or set-off of any other amount;

     (b)  make that payment:

          (i)  if Novogen Laboratories must pay GST on or after receiving the
               consideration or any part of it - as and when Glycotex must pay
               or provide the consideration or that part of it;

          (ii) if Novogen Laboratories must pay GST on issuing an invoice under
               this document - on the earlier of the due date for payment of
               that invoice, or 10 Business Days following the end of the month
               in which Novogen Laboratories issued that invoice; and

          (iii) if Novogen Laboratories must pay GST upon the occurrence of some
               other event - within 5 Business Days of a written request by
               Novogen Laboratories for payment for the GST, which may be in the
               form of a tax invoice (or an adjustment note); and

     (c)  indemnify Novogen Laboratories against, and pay Novogen Laboratories
          on demand the amount of:

          (i)  all GST on the transactions contemplated by this document; and

          (ii) any loss, liability or expense directly or indirectly incurred in
               connection with or arising from or caused by any failure by
               Glycotex to pay any amount as and when required by this clause 5
               for example, any additional tax, penalty tax, fine, interest or
               other charge under a GST Law.

5.3  TAX INVOICE

     Within 28 days of a written request from Glycotex, Novogen Laboratories
     must issue a tax invoice (or an adjustment note) to Glycotex for any supply
     for which Novogen Laboratories may recover GST from Glycotex under this
     document, and must include in the tax invoice (or adjustment note) the
     particulars required by the GST Law for Glycotex to obtain an input tax
     credit for that GST.

                                                                              8.
<PAGE>
5.4  ADJUSTMENTS

     Novogen Laboratories must refund to Glycotex any overpayment by Glycotex
     for GST, but Novogen Laboratories need not refund to Glycotex any amount
     for GST paid to the Commissioner of Taxation unless Novogen Laboratories
     has received a refund or credit of that amount.

5.5  GST WHERE GLYCOTEX SUPPLIES NOVOGEN LABORATORIES

     If Glycotex must pay GST for anything provided or supplied by Glycotex
     under this document, Novogen Laboratories must pay to Glycotex an amount
     equal to that GST in exactly the same way as Glycotex must so do for any
     GST Novogen Laboratories must pay, and this clause 5 applies to that GST as
     if Glycotex was Novogen Laboratories, and Novogen Laboratories was
     Glycotex.

6.   MATERIALS AND INTELLECTUAL PROPERTY RIGHTS

6.1  MATERIALS AND INFORMATION

     Novogen Laboratories acknowledges that all materials, Know How and other
     information made available by Glycotex to Novogen Laboratories in the
     performance of the parties' obligations under this document remain the
     property of Glycotex.

6.2  INTELLECTUAL PROPERTY RIGHTS

     As between Glycotex and Novogen Laboratories, all Intellectual Property
     Rights created or developed by or on behalf of Novogen Laboratories in the
     performance of:

     (a)  its obligations under this document; and

     (b)  Glycotex's obligations under Clinical Trial Agreements,

     vest exclusively in Glycotex immediately upon their creation, and by this
     document Novogen Laboratories assigns to Glycotex absolutely and as
     beneficial owner its entire right and title to and interest in all such
     Intellectual Property Rights.

7.   CONFIDENTIAL INFORMATION

7.1  CONFIDENTIALITY

     Novogen Laboratories shall:

     (a)  keep and maintain all Confidential Information strictly confidential;

     (b)  use Confidential Information only for the purposes for which it is
          disclosed; and

     (c)  not disclose Confidential Information other than to its employees,
          authorised sub-contractors, legal advisers, auditors or other
          consultants requiring the information for the purposes of this
          document and then only upon those persons undertaking in writing to
          keep that information strictly confidential.

                                                                              9.
<PAGE>
7.2  EXCEPTIONS TO OBLIGATIONS OF CONFIDENTIALITY

     The obligations in clauses 7.1 do not apply to the extent that Novogen
     Laboratories is required by law to disclose the Confidential Information,
     provided that it promptly gives notice to Glycotex of that requirement and
     discloses only that part of the Confidential Information which it is
     legally required to disclose.

7.3  PUBLIC DOMAIN

     No Confidential Information shall be deemed to be in the public domain
     merely because it contains information which is in the public domain or is
     embraced by a general disclosure which is in the public domain.

8.   REPRESENTATIONS AND WARRANTIES

8.1  WARRANTIES OF EACH PARTY

     Each party represents and warrants that:

     (a)  (POWER) it has full legal capacity and power to:

          (i)  own its property and to carry on its business; and

          (ii) enter into this document and to carry out the transactions that
               this document contemplates;

     (b)  (CORPORATE AUTHORITY) it has taken all corporate action that is
          necessary or desirable to authorise its entry into this document and
          its carrying out the transactions that this document contemplates;

     (c)  (DOCUMENTS EFFECTIVE) this document constitutes its legal, valid and
          binding obligations, enforceable against it in accordance with its
          terms (except to the extent limited by equitable principles and laws
          affecting creditors' rights generally), subject to any necessary
          stamping or registration;

     (d)  (NO CONTRAVENTION) neither its execution of this document nor the
          carrying out by it of the transactions that this document
          contemplates, does or will:

          (i)  contravene any law to which it or any of its property is subject
               or any order of any Government Agency that is binding on it or
               any of its property;

          (ii) contravene any undertaking or instrument binding on it or any of
               its property;

          (iii) contravene its constitution; or

          (iv) require it to make any payment or delivery in respect of any
               financial indebtedness before it would otherwise be obliged to do
               so; and

     (e)  (NO TRUST) it is not entering into this document as trustee of any
          trust or settlement.

                                                                             10.
<PAGE>
8.2  RELIANCE ON REPRESENTATIONS AND WARRANTIES

     Each party acknowledges that the other party has executed this document and
     agreed to take part in the transactions that this document contemplates in
     reliance on the representations and warranties that are made in this clause
     8.

8.3  EXCLUSION OF CONDITIONS AND WARRANTIES

     Except for the warranties expressly made in this document, all conditions,
     warranties, undertakings or representations express or implied arising by
     statute, general law or otherwise are expressly excluded to the extent
     permitted by law.

9.   LIMITATION OF LIABILITY AND INDEMNITY

9.1  INDIRECT AND CONSEQUENTIAL LOSS

     Despite any other provision of this document, and to the extent permitted
     by law, in no circumstances is Novogen Laboratories liable in contract,
     tort (including negligence or breach of statutory duty) or otherwise, and
     whatever the cause, to compensate Glycotex for:

     (a)  any increased costs or expenses;

     (b)  any economic loss, loss of profit, revenue, business, contracts or
          anticipated savings; or

     (c)  any other special, indirect or consequential loss or damage of any
          nature.

9.2  INDEMNITY

     Glycotex must indemnify and keep indemnified Novogen Laboratories, its
     directors, employees and agents against all damages, costs or expenses
     (including legal costs and expenses on an indemnity basis) in respect of
     any claims, demands, actions, proceedings or prosecution which may be
     brought or commenced as a result of or in relation to:

     (a)  any breach of any Clinical Trial Agreement; or

     (b)  any personal injury to or death of any person:

          (i)  enrolled in a Clinical Trial;

          (ii) arising out of or relating to the administration of a Glucan
               Product; or

          (iii) arising out of or relating to any clinical intervention or
               procedure during or as a result of a Clinical Trial;

     (c)  the sale, distribution or other commercialisation or exploitation of
          Glucan Products; or

     (d)  any packaging, marketing, advertisement or promotion of Glucan
          Products.

                                                                             11.
<PAGE>
10.  FORCE MAJEURE

10.1 NOTICE AND SUSPENSION OF OBLIGATIONS

     If a party to this document is affected, or likely to be affected, by a
     Force Majeure Event:

     (a)  that party must immediately give the other prompt notice of that fact
          including:

          (i)  full particulars of the Force Majeure Event;

          (ii) an estimate of its likely duration;

          (iii) the obligations affected by it and the extent of its effect on
               those obligations; and

          (iv) the steps taken to rectify it; and

     (b)  the obligations under this document of the party giving the notice are
          suspended to the extent to which they are affected by the relevant
          Force Majeure Event as long as the Force Majeure Event continues.

10.2 EFFORT TO OVERCOME

     A party claiming a Force Majeure Event must use its best endeavours to
     remove, overcome or minimise the effects of that Force Majeure Event as
     quickly as possible. However, this does not require a party to settle any
     industrial dispute in any way it does not want to.

10.3 TERMINATION

     If a Force Majeure Event continues for more than 3 months, any party may
     terminate this document by giving at least 10 Business Days notice to the
     other party.

11.  TERM AND TERMINATION

11.1 TERM

     The rights and obligations of the parties under this document begin on the
     Commencement Date and continue until this document is terminated in
     accordance with this clause 11.

11.2 TERMINATION BY GLYCOTEX

     Glycotex may terminate this document at any time:

     (a)  on three month's written notice to Novogen Laboratories;

     (b)  immediately if Novogen Laboratories defaults in the performance of any
          of its obligations under this document which in Glycotex's reasonable
          opinion is capable of remedy and fails to remedy that default within
          21 days of receiving written notice from Glycotex specifying the
          default and requiring the default to be remedied;

                                                                             12.
<PAGE>
     (c)  on 21 days written notice if Novogen Laboratories defaults in the
          performance of any of its material obligations under this document
          which in Glycotex's reasonable opinion is not capable of remedy; and

     (d)  immediately by notice in writing if:

          (i)  Novogen Laboratories is involved in an Insolvency Event; or

          (ii) Novogen Laboratories ceases for any reason to be able lawfully to
               carry out all the transactions which this document contemplates
               may be carried out by Novogen Laboratories.

11.3 TERMINATION BY NOVOGEN LABORATORIES

     Novogen Laboratories may terminate this document at any time:

     (a)  immediately if Glycotex defaults in the performance of any of its
          obligations under this document which in Novogen Laboratories'
          reasonable opinion is capable of remedy and fails to remedy that
          default within 21 days of receiving written notice from Novogen
          Laboratories specifying the default and requiring the default to be
          remedied;

     (b)  on 21 days written notice if Glycotex defaults in the performance of
          any of its material obligations under this document which in Novogen
          Laboratories' reasonable opinion is not capable of remedy; and

     (c)  immediately by notice in writing if:

          (i)  there is a Change in Control of Glycotex without Novogen
               Laboratories' written consent;

          (ii) Glycotex is involved in an Insolvency Event; or

          (iii) Glycotex ceases for any reason to be able lawfully to carry out
               all the transactions which this document contemplates may be
               carried out by Glycotex.

11.4 CONSEQUENCES OF TERMINATION

     Upon expiration or termination of this document for any reason Novogen
     Laboratories must deliver to Glycotex or destroy at Glycotex's election,
     all Confidential Information in Novogen Laboratories' possession, custody
     or power.

11.5 SURVIVAL AND ACCRUED RIGHTS

     Upon termination under this clause 11, this document is at an end as to its
     future operation except for:

     (a)  the enforcement of any right or claim which arises on or has arisen
          before termination; and

                                                                             13.
<PAGE>
     (b)  the obligations of the parties under clauses 1, 6, 7, 9, 12, 13, 14,
          15 (except clause 15.4) and this clause 11, which survive termination.

12.  DISPUTE RESOLUTION

12.1 DISPUTES

     If a dispute arises out of or in relation to this document (including any
     dispute as to breach or termination of the document or as to any claim in
     tort, in equity or pursuant to any statute) (a DISPUTE), a party to this
     document may not commence any court or arbitration proceedings relating to
     the Dispute unless it has complied with this clause 12 except where the
     party seeks urgent interlocutory relief.

12.2 NOTICE OF DISPUTE

     A party to this document claiming that a Dispute has arisen under or in
     relation to this document must give written notice to the other party
     specifying the nature of the Dispute (a DISPUTE NOTICE).

12.3 NEGOTIATION

     Upon receipt by a party of a Dispute Notice, Novogen Laboratories and
     Glycotex must procure that their respective Managing Directors meet to
     endeavour to resolve the Dispute expeditiously by negotiation.

12.4 RESOLUTION OF DISPUTE

     If the parties have not resolved the Dispute under clause 12.3 within 14
     days of receipt of a Dispute Notice, the parties must endeavour to resolve
     the Dispute expeditiously using informal dispute resolution techniques such
     as mediation, expert evaluation or determination or similar techniques
     agreed by the parties.

12.5 MEDIATION

     If the parties do not agree within 28 days of receipt of a Dispute Notice
     (or such further period as the parties agree in writing) as to:

     (a)  the dispute resolution technique and procedures to be adopted;

     (b)  the timetable for all steps in those procedures; and

     (c)  the selection and compensation of the independent person required for
          such technique,

     the parties must mediate the Dispute in accordance with the Mediation Rules
     of the Law Society of New South Wales, and the President of the Law Society
     of New South Wales (or the President's nominee) will select the mediator
     and determine the mediator's remuneration.

                                                                             14.
<PAGE>
13.  NOTICES

     (a)  A notice, consent or other communication under this document is only
          effective if it is in writing, signed and either left at the
          addressee's address or sent to the addressee by mail or fax. If it is
          sent by mail, it is taken to have been received 3 working days after
          it is posted. If it is sent by fax, it is taken to have been received
          when the addressee actually receives it in full and in legible form.

     (b)  The parties' addresses and fax numbers are those set out below, or as
          a party notifies the other:

          GLYCOTEX
          Address:               140 Wicks Road North Ryde, NSW 2113 AUSTRALIA
          Fax number:            Int + 612 9878 0055
          Attention:             The President

          NOVOGEN LABORATORIES
          Address:               140 Wicks Road North Ryde, NSW 2113 AUSTRALIA
          Fax number:            Int + 612 9878 0055
          Attention:             Managing Director

14.  AMENDMENT AND ASSIGNMENT

14.1 AMENDMENT

     This document can only be amended, supplemented, replaced or novated by
     another document signed by the parties.

14.2 ASSIGNMENT

     A party may only dispose of, declare a trust over or otherwise create an
     interest in its rights under this document with the other party's consent.

15.  GENERAL

15.1 GOVERNING LAW

     (a)  This document is governed by the law in force in New South Wales,
          Australia.

     (b)  Each party submits to the non-exclusive jurisdiction of the courts
          exercising jurisdiction in New South Wales, and any court that may
          hear appeals from any of those courts, for any proceedings in
          connection with this document, and waives any right it might have to
          claim that those courts are an inconvenient forum.

15.2 LIABILITY FOR EXPENSES

     Each party must pay its own expenses incurred in negotiating, executing,
     stamping and registering this document.

                                                                             15.
<PAGE>
15.3 RELATIONSHIP OF THE PARTIES

     (a)  Nothing in this document creates a relationship of employment,
          partnership or joint venture between the parties under the laws of any
          applicable jurisdiction.

     (b)  Except as expressly provided in this document, no party may act or has
          any authority to act as agent of or in any way bind or commit the
          other party to any obligation.

15.4 GIVING EFFECT TO THIS DOCUMENT

     Each party must do anything (including execute any document), and must
     ensure that its employees and agents do anything (including execute any
     document), that the other party may reasonably require to give full effect
     to this document.

15.5 WAIVER OF RIGHTS

     A right may only be waived in writing, signed by the party giving the
     waiver, and:

     (a)  no other conduct of a party (including a failure to exercise, or delay
          in exercising, the right) operates as a waiver of the right or
          otherwise prevents the exercise of the right;

     (b)  a waiver of a right on one or more occasions does not operate as a
          waiver of that right if it arises again; and

     (c)  the exercise of a right does not prevent any further exercise of that
          right or of any other right.

15.6 OPERATION OF THIS DOCUMENT

     (a)  This document contains the entire agreement between the parties about
          its subject matter. Any previous understanding, agreement,
          representation or warranty relating to that subject matter is replaced
          by this document and has no further effect.

     (b)  Any right that a person may have under this document is in addition
          to, and does not replace or limit, any other right that the person may
          have.

     (c)  Any provision of this document which is unenforceable or partly
          unenforceable is, where possible, to be severed to the extent
          necessary to make this document enforceable, unless this would
          materially change the intended effect of this document.

15.7 EXCLUSION OF CONTRARY LEGISLATION

     Any legislation that adversely affects an obligation of a party, or the
     exercise by a party of a right or remedy, under or relating to this
     document is excluded to the full extent permitted by law.

                                                                             16.
<PAGE>
15.8 COUNTERPARTS

     This document may be executed in counterparts.

EXECUTED as an agreement.

EXECUTED by GLYCOTEX, INC.:

/s/ David Seaton                        /s/ David Seaton
-------------------------------------   ----------------------------------------
Signature of director                   Signature of director/secretary

DAVID SEATON                            DAVID SEATON
-------------------------------------   ----------------------------------------
Name                                    Name

EXECUTED by NOVOGEN
RESEARCH PTY LIMITED:

/s/ Christopher Naughton                /s/ Ron Lea Erratt
-------------------------------------   ----------------------------------------
Signature of director                   Signature of director/secretary

CHRISTOPHER NAUGHTON                    RON LEA ERRATT
-------------------------------------   ----------------------------------------
Name                                    Name

                                                                             17.<PAGE>

                                                                     Exhibit 4.2

PREFERRED STOCK                                                  PREFERRED STOCK

NUMBER                          [LOGO OF EAGLE]                           SHARES
NTR Pr
                                                              CUSIP
                                                               SEE REVERSE FOR
                                                             CERTAIN DEFINITIONS

                          NEW YORK MORTGAGE TRUST, INC.
              INCORPORATED UNDER THE LAWS OF THE STATE OF MARYLAND

THIS CERTIFIES THAT                                                       NYMT
                                                                          NEW
                                                                          YORK
                                                                        MORTGAGE
                                                                         TRUST
is the holder of

            FULLY PAID AND NON-ASSESSABLE SHARES OF PREFERRED STOCK,
                          $0.01 PAR VALUE PER SHARE, OF

                          NEW YORK MORTGAGE TRUST, INC.

transferable on the books of the Corporation in person or by duly authorized
attorney upon surrender of this Certificate properly endorsed. This Certificate
is not valid until countersigned by the Transfer Agent and registered by the
Registrar.

     WITNESS the facsimile seal of the Corporation and the facsimile signatures
of its duly authorized officers.

DATED

NTR                   /s/ MICHAEL I. WIRTH
LISTED              EXECUTIVE VICE PRESIDENT,
NYSE                 CHIEF FINANCIAL OFFICER             /s/ STEVEN B. SCHNALL
                          AND SECRETARY               CO-CHIEF EXECUTIVE OFFICER
                         [NEW YORK MORTGAGE TRUST SEAL]

                                         COUNTERSIGNED AND REGISTERED:
                                    AMERICAN STOCK TRANSFER & TRUST COMPANY
                                              (New York, New York)

                                                                  Transfer Agent
                                                                   and Registrar
                                         By
                                                            Authorized Signature

<PAGE>

                          NEW YORK MORTGAGE TRUST, INC.

                                IMPORTANT NOTICE

     The Company will furnish to any stockholder upon request and without charge
a full statement of the designations, preferences, conversion and other rights,
voting powers, restrictions, limitations as to dividends, qualifications, and
terms and conditions of redemption of shares of each class authorized to be
issued and, with respect to the classes of shares which may be issued in series,
the differences in the relative rights and preferences between the shares of
each services, to the extent they have been set. Such request may be made to the
Secretary of the Company at its principal office or to the Transfer Agent.

     The securities represented by this certificate are subject to restrictions
on ownership and transfer contained in the Articles of Amendment and Restatement
of the Company (the "Charter") for the purpose of the Company's maintenance of
its status as a real estate investment trust under the Internal Revenue Code of
1986, as amended. A copy of the Charter and information about the restrictions
in affect will be furnished by the Company to any holder of this certificate
upon request and without charge. All capitalized terms in this legend have the
meanings defined in the Charter of the Company. If the restrictions on ownership
or transfer are violated, the securities represented hereby will be designated
and treated as Shares which will be held in the Charitable Trust by the Company.

     The following abbreviations, when used in the inscription on the face of
this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:

TEN COM - as tenants in common

TEN ENT - as tenants by the entireties

JT TEN - as joint tenants with right of survivorship and not as tenants in
common.

UNIF GIFT MIN ACT-   _____________________________Custodian_____________________
                            (Cust)                              (Minor)
                     under Uniform Gifts to Minors

                     Act _______________________________________________________
                                          (State)

UNIF TRF MIN ACT-    ________________________Custodian (until age _____________)
                            (Cust)

                     ____________________________________under Uniform Transfers
                            (Minor)

                     to Minors Act _____________________________________________
                                                     (State)

     Additional abbreviations may also be used though not in the above list.

For Value received, ______________________ hereby sell, assign and transfer unto

PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE

_____________________________________

_____________________________________

________________________________________________________________________________
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)

<PAGE>

________________________________________________________________________________

________________________________________________________________________________

_________________________________________________________________________ Shares
of the Preferred Stock represented by the within Certificate, and do(es) hereby
irrevocably constitute and appoint _____________________________________________
Attorney to transfer the said Preferred Stock on the books of the within named
Corporation with full power of substitution in the premises.

Dated ___________________________          X ___________________________________

                                           X ___________________________________

                                     NOTICE: THE SIGNATURE(S) TO THIS ASSIGNMENT
                                             MUST CORRESPOND WITH THE NAME(S) AS
                                             WRITTEN UPON THE FACE OF THE
                                             CERTIFICATE IN EVERY PARTICULAR
                                             WITHOUT ALTERATION OR ENLARGEMENT
                                             OR ANY CHANGE WHATEVER.

SIGNATURES GUARANTEED:

By _____________________________________________________________________________
   THE SIGNATURES(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
   (BANKS, STOCKHOLDERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH
   MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO
   S.E.C. RULE 17Ad-15.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]